Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082824 | 0.86 | ACHE (0.54) | HSD17B1ACHEPBRM1BRD4KMT2A | |
| SCHEMBL662848 | 0.81 | ACHE (0.57) | ACHEPBRM1MAOA | |
| SCHEMBL7429220 | 0.78 | MAOB (0.51) | PBRM1ALDH1A1MAOA | |
| SCHEMBL30701777 | 0.77 | HTR2A (0.43) | HSD17B1ACHEPBRM1BRD4MEN1 | |
| SCHEMBL27029704 | 0.77 | HTR2A (0.43) | HSD17B1ACHEPBRM1BRD4MEN1 | |
| SCHEMBL9620680 | 0.77 | ACHE (0.51) | HSD17B1ACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL6199828 | 0.75 | PTGS2 (0.56) | HSD17B1ACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL3081446 | 0.75 | PTGS2 (0.59) | HSD17B1ACHEPBRM1ALDH1A1MAOA | |
| SCHEMBL2932814 | 0.74 | PBRM1 (0.57) | HSD17B1ACHEPBRM1MEN1KMT2A | |
| SCHEMBL17043164 | 0.74 | ACHE (0.42) | HSD17B1ACHEPBRM1BRD4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | JOYOCHEM CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-7816390-B2 | N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-7816390-B2 | N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080227821-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227821-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
| WO-2008094896-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-07 | — | — | WO | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| EP-1682516-A2 | IMMOBILIZED N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES FOR THE IDENTIFICATION OF BIOMOLECULAR TARGETS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050130910-A1 | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | disclosed |
| WO-2005049579-A2 | IMMOBILIZED N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES FOR THE IDENTIFICATION OF BIOMOLECULAR TARGETS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-02 | — | — | WO | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227821-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS ANTI-MITOTIC TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | HSD17B1 1641/4885ACHE 3193/4885PBRM1 352/4885 |
| US-20170327468-A1 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF 1-METHYL-1, 4-DIHYRDOINDENO[1,2-C]PYRAZOLE ANALOGUES AS POTENTIAL ANTICANER AGENTS TARGETING TUBULIN COLCHICINE BINDING SITE | TUBA1C, TUBB1, TUBB3 | HSD17B1 455/4885ACHE 2210/4885PBRM1 3136/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | HSD17B1 2188/4885ACHE 4821/4885PBRM1 530/4885 |
| US-20050130910-A1 | Immobilized N-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets | ABAT, NAT1, AADAC | HSD17B1 1151/4885ACHE 2944/4885PBRM1 1320/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | HSD17B1 2361/4885ACHE 4811/4885PBRM1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.